EMEA looks at drug safety research
The European Medicines Agency (EMEA) has released another priority for drug safety research in 2010 - studies into the long-term adverse skeletal effects of bisphosphonates. It has also released an opinion on bisphosphonates and osteonecrosis of the jaw.
The European Medicines Agency (EMEA) has released another priority for drug safety research in 2010 - studies into the long-term adverse skeletal effects of bisphosphonates. It has also released an opinion on bisphosphonates and osteonecrosis of the jaw.
In addition, EMEA has released more information on the payment of fees for its services.
It has also detailed procedures for consulting environmental authorities on genetically modified organisms regarding environmental risk assessment for medicine development.
EMEA has also released information on a recent internal reorganisation.